Genetic test could shorten hospital stays for fungal infection patients
NCT ID NCT03554239
First seen Jun 29, 2026 · Last updated Jun 30, 2026 · Updated 1 time
Summary
This study explores whether a genetic test (CYP2C19) can help doctors choose the right dose of the antifungal drug voriconazole more quickly. Patients starting voriconazole for an infection will give a blood sample for genotyping. The goal is to see if this personalized dosing reduces the number of days spent in the hospital compared to standard monitoring.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- genetic test (CYP2C19 genotyping)
- What this could lead to
- If successful, this approach could help doctors personalize antifungal dosing, potentially shortening hospital stays and reducing side effects.
- What could go wrong
- This is a small, early-stage study focused on feasibility. Genetic testing may not significantly change outcomes, and results may not apply to broader populations.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for INFECTION are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Aging in place: could mobile teams keep nursing home residents out of the hospital?
- A pillow shaped to protect the spine after surgery — a small trial puts it to the test
- Drone Warfare's hidden toll: new study tracks infection risk in combat wounds
- Rapid molecular tests could help doctors prescribe antibiotics more precisely
- Do future doctors know the skin risks of tattoos and piercings?
- Smart insulin pump could transform hospital diabetes care